UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors

Exclusion Criteria

• •(1) Patients with continuous use of immunosuppressants within 1 month before infusion of UTAA06 injection;
• •(2) cerebrovascular accident or convulsive attack occurred within 6 months before signing the informed consent;
• •(3) Hepatitis B surface antigen (HBsAg) positive or hepatitis B core antibody (HBcAb) positive, and hepatitis B virus (HBV) DNA titer detected by peripheral blood is not within the normal reference value range; Hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA positive; Human immunodeficiency virus (HIV) antibody positive; EBV DNA test positive; cytomegalovirus (CMV) DNA test positive; Syphilis positive;
• •(4) Serious heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (NYHA classification ≥III), and severe arrhythmia;
• •(5) Other unstable systemic diseases as determined by the researcher;
• •(6) had other uncured malignant tumors within the past 5 years or at the same time, except for in situ cervical cancer, skin basal cell carcinoma and other in situ cancers;
• •(7) Chronic progressive nervous system disease;
• •(8) Patients who have not yet recovered from the acute toxic effects of prior treatment (hematological or organ toxicity \> Grade 2 caused by prior treatment, except those related to the studied disease and medical history);
• •(9) Previous or current graft-versus-host disease (GVHD);
• •(10) There is an active or uncontrolled infection that requires systemic treatment (except for mild genitourinary and upper respiratory tract infections);
• •(11) Female subjects who are capable of becoming pregnant and plan to become pregnant within 2 years after the cell infusion; Or a male subject whose partner plans to become pregnant within 2 years of the cell infusion;
• •(12) Participating in clinical studies of other innovative drugs within 1 month before screening;
• •(13) Evidence of central nervous system invasion during subject screening;
• •(14) For patients with liver metastases, the researchers judged that the tumor load of liver metastases was too large to be eligible for inclusion in this clinical trial.
• •(15) Situations considered unsuitable for inclusion by other researchers.